Experienced in Dementia

Richard C. Bergeron

Guelph, ON, CA 
Experienced in Dementia
Guelph, ON, CA 
OverviewLocationsClinical Research

Overview

Richard Bergeron practices in Guelph, Canada. Mr. Bergeron is rated as an Experienced expert by MediFind in the treatment of Dementia. His top areas of expertise are Alzheimer's Disease, Dementia, Cramp-Fasciculation Syndrome, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 11 clinical trials in the study of Dementia.

Gender
Male

Locations

Guelph, ON N1G2W1, Canada
Other Locations
Guelph, Canada
451 Smyth Road, Room 3501N, Ottawa, ON K1H8M5, Canada
Vancouver, BC V6T1Z3, Canada
Alfred, ON K0B1A0, Canada
Montreal, QC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
Enrollment Status: Completed
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 2
Retinal Deep PhenotypingTM Platform for Cerebral Amyloid Status Evaluation: a Validation Study
Retinal Deep PhenotypingTM Platform for Cerebral Amyloid Status Evaluation: a Validation Study
Enrollment Status: Completed
Publish Date: August 07, 2024
Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease
Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease
Enrollment Status: Suspended
Publish Date: January 25, 2023
Intervention Type: Device
Study Phase: Not Applicable
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
Enrollment Status: Completed
Publish Date: April 30, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
View 10 Less Clinical Trials

53 Total Publications

Effect of training dairy heifers to an automated milking system before parturition on their adaptation and performance.
Effect of training dairy heifers to an automated milking system before parturition on their adaptation and performance.
Journal: Journal of dairy science
Published: May 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bergeron's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile